A pre-clinical study in the United States confirmed that the drug Trilexium (TRXE-009) can destroy brain cancer cells that resist chemotherapy and cause tumors to return. The drug is effective both in children and adults.
The study, conducted at the Feinstein Institute for Medical Research, studied the effects of the drug on brain cancer cells taken from patients.
Participants in the study had had glioblastoma multiform (GBM), the most common and aggressive type of brain cancer.
“Killing these highly-resistant GBM cancer stem cells is considered to be a fundamental requirement to successfully treating this highly destructive disease,” the drug’s developer, Novogen. “All patient derived cancer cells represented in the library responded to TRXE-009 at clinically relevant doses, suggesting a strong therapeutic potential.”
Novogen developed Trilexium to cross the blood-brain barrier, which blocks most chemotherapeutic drugs from reaching brain tissue.
The company is also collaborating with the Feinstein Institute on different methods to deliver the drug, including by direct injection into cancer cells and intravenously.
Novogen hopes to launch a phase 1 clinical trial of the drug in early 2016. The clinical trials are extremely interesting in the context of previous attempts with TRXE-009 showing high toxicity in other types of pediatric brain cancers.